Pomalidomide is a cancer medicine that promotes an immune response to help slow tumor growth. It is used in combination with dexamethasone to treat people with relapsed/refractory multiple myeloma who have received at least two prior medicines to treat their myeloma (including a type of medicine known as a proteasome inhibitor and lenalidomide).

SparkCures ID 5
Developed By Celgene Corporation
Brand Name Pomalyst®
Generic Name Pomalidomide
Additional Names CC-4047, Actimid
Treatment Classifications

Clinical Trials


There are no resources, links or videos to display for this treatment.